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Abstract
An HIV-1 vaccine capable of providing sterilizing immunity from vaginal infection would reduce
the spread of HIV-1 to women. Unfortunately, only one of the four HIV-1 vaccine clinical trials
has demonstrated any level of protection (31%) against HIV-1 transmission. Additionally, only
one topical microbicide clinical trial has reported an overall reduction in HIV-1 transmission
(39%). Developing even more effective vaccines and microbicides will require a better
understanding of the key events involved in HIV-1 infection and dissemination at the site of
exposure. Novel immunodeficient mice capable of being systemically reconstituted with human
hematopoietic stem cells have provided new systems where HIV transmission studies can be
performed. Specifically, a humanized mouse model of vaginal HIV transmission has been
developed that utilizes the humanized bone marrow-liver-thymus (BLT) mouse. The female
reproductive tract (FRT) of humanized BLT mice is reconstituted with functional human immune
cells rendering them susceptible to vaginal HIV-1 infection. In this review we focus on four
aspects of BLT mice for the study of vaginal HIV-1 transmission: 1) we discuss methods for
creating humanized BLT mice and their reconstitution with human hematopoietic cells, 2) we
describe reconstitution of the BLT mouse FRT with human immune cells, 3) we highlight the
work done regarding vaginal HIV-1 transmission and 4) we summarize the efficacy of systemic
pre-exposure prophylaxis (PrEP) to prevent vaginal HIV-1 transmission in BLT mice. BLT mice
are a highly relevant small animal model for studying vaginal HIV-1 transmission, prevention and
therapy.
1. Introduction
In 2008, UNAIDS and the World Health Organization estimated that worldwide there are
33.4 million people infected with human immunodeficiency virus 1 (HIV-1)1.
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Approximately half of those individuals are women. The prevalence of HIV-1 in women is
even higher in areas like sub-Saharan Africa, the region with the highest incidence and
prevalence of HIV-1, where social and economic conditions increase the probability that
women will be exposed to HIV-1 (UNAIDS, 2009).
An HIV-1 vaccine capable of providing sterilizing immunity from vaginal infection would
reduce the spread of HIV-1 to women. Unfortunately, only one of the four HIV-1 vaccine
clinical trials, the ALVAC/AIDSVAX vaccine trial, has demonstrated any level of
protection (31%) against HIV-1 transmission (Padian et al., 2010). In addition to the four
HIV-1 vaccine clinical trials, several topical microbicides have been clinically tested for
their ability to prevent vaginal HIV-1 transmission (Padian et al., 2010). The only successful
microbicide clinical trial to date, CAPRISA 004, reported an overall reduction of 39% in
HIV-1 transmission when a 1% gel formulation of the antiretroviral tenofovir was applied
vaginally before and after vaginal intercourse. More impressively, a 54% decrease in HIV-1
infection was demonstrated among patients with >80% compliance (Abdool Karim et al.,
2010). These successes demonstrate that HIV-1 vaccines and antiretroviral microbicides
have the potential to reduce the global spread of HIV-1.
Developing even more effective vaccines and microbicides capable of fully protecting
women from HIV-1 infection will require a better understanding of the key events involved
in HIV-1 infection and dissemination at the site of exposure. Ex vivo tissue explants and
epithelial sheets of the female reproductive tract (FRT) have provided valuable insight into
three critical aspects of HIV-1 infection: 1) the anatomical sites of the FRT that support high
levels of HIV-1 replication (Asin et al., 2009), 2) the early events of HIV-1 infection
including the specific immune cell populations preferentially targeted by HIV-1 (Hladik et
al., 2007, Gupta et al., 2002, Saba et al., 2010) and 3) the factors that influence HIV-1
transmission such as mucosal epithelium and inflammatory mediators (Asin et al., 2009,
Greenhead et al., 2000). These ex vivo models of the FRT have also been used to screen
potential antiretroviral microbicide candidates (Greenhead et al., 2000, Rohan et al., 2010).
Although a wealth of knowledge has been gathered from these studies, ex vivo models
cannot be used to test the efficacy of HIV-1 vaccines nor can they model key aspects of
human biology that affect the in vivo infection process like hormonal regulation of the FRT,
the mucosal immune response and viral dissemination into other tissues.
1.1. Animal models of HIV-1 infection
Non-human primate models using simian immunodeficiency virus (SIV) have served as the
primary in vivo animal model for evaluating the efficacy of potential vaccines and
microbicides (Van Rompay, 2010, Uberla, 2005, Veazey, 2008). In addition, macaques have
been used to study rectal and vaginal SIV transmission (Keele et al., 2009, Miller et al.,
2005). Macaque models provide access to relevant anatomical compartments where the
early events taking place in the FRT can be studied. Despite the utility of macaque models,
these studies are limited by the inability of HIV-1 to productively infect macaque cells, an
issue that has been partially overcome by the use of SIV/HIV chimeric viruses (SHIVs)
(Harouse et al., 1999). Despite their current utility, SHIVs require further refinement before
they can serve as faithful surrogates of HIV-1, particularly in the context of HIV-specific
pharmacological interventions to prevent vaginal HIV-1 transmission (Van Rompay, 2010).
Novel strains of immunodeficient mice capable of being systemically reconstituted with
human hematopoietic stem cells have provided new systems where in vivo HIV studies can
be performed (Denton and Garcia, 2009). Specifically, a humanized mouse model of vaginal
HIV transmission has been developed that utilizes the humanized bone marrow-liver-thymus
(BLT) mouse. The FRT of humanized BLT mice is reconstituted with functional innate and
adaptive human immune cells rendering them susceptible to vaginal HIV-1 infection
Olesen et al. Page 2













(Denton et al., 2008). In this review we focus on four aspects of BLT mice for the study of
vaginal HIV-1 transmission: 1) we discuss methods for creating humanized BLT mice and
their systemic reconstitution with human hematopoietic cells, 2) we describe the
reconstitution of the BLT mouse FRT with human immune cells, 3) we highlight work done
regarding vaginal HIV-1 transmission in this system and 4) we summarize the efficacy of
systemic pre-exposure prophylaxis (PrEP) to prevent vaginal HIV-1 transmission in BLT
mice.
2. The humanized BLT mouse model
2.1. Generation of BLT mice
Humanized BLT mice are individually created by transplanting human fetal liver-derived
CD34+ hematopoietic stem cells into mice implanted with autologous human fetal liver and
thymus. A sandwich of 1–2 mm pieces of human fetal thymus-liver-thymus tissue is
implanted under the kidney capsule of 6 to 8 week old NOD/SCID mice or NOD/SCID/
γc−/− mice (stock number 00557, NSG mice; The Jackson Laboratory). In comparison to
other immunodeficient strains of mice like SCID, both NOD/SCID and NOD/SCID/γc−/−
mice have a lower level of endogenous mouse natural killer (NK) cell activity which
facilitates more prolonged and robust human immune cell reconstitution (Greiner et al.,
1998, Shultz et al., 2005). Mice are exposed to sublethal gamma irradiation (325 centi-Gray
(cGy) for NOD/SCID mice and 300 cGy for NOD/SCID/γc−/− mice) 4–24 hours prior to
transplantation of CD34+ stem cells (1–2.5 × 106 and 2.5–8 × 105 CD34+ cells for NOD/
SCID and NOD/SCID/γc−/− mice, respectively) to facilitate engraftment. The irradiation
and transplant can be performed the same day of implantation or three weeks after
implantation with equivalent results. The transplanted CD34+ cells engraft and some
maintain their progenitor potential while others differentiate into different hematopoietic
lineages (i.e. CD3+, CD19+, CD14+ etc.) (Sun et al., 2007, Denton et al., 2008, Melkus et
al., 2006, Brainard et al., 2009, Rajesh et al., 2010, Denton et al., 2010, Lan et al., 2006).
In BLT mice the implanted fetal thymus tissue develops into a human thymus (thymic
organoid) where bone marrow derived human T lymphocyte progenitor cells can migrate
and develop within the context of autologous human thymic epithelium into bona fide, fully
functional, HLA-restricted peripheral T cells (Brainard et al., 2009, Melkus et al., 2006,
Rajesh et al., 2010, Lan et al., 2006). Thus, BLT mice are characterized by their robust and
sustained systemic repopulation with functional HLA-restricted human T cells.
2.2. Human immune cell reconstitution in peripheral blood of BLT mice
The utility of BLT mice as an animal model for HIV hinges on their sustained reconstitution
with human hematopoietic CD45+ cells. Human immune cell reconstitution in peripheral
blood of BLT mice and the phenotype of the human immune cells present is routinely
analyzed by flow cytometry (Melkus et al., 2006, Rajesh et al., 2010, Brainard et al., 2009,
Lan et al., 2006) (Fig. 1). Human innate and adaptive immune cells can be detected in
peripheral blood of BLT mice as early as four to eight weeks post-transplant in NOD/SCID/
γc−/− and NOD/SCID BLT mice respectively, and is maintained for over nine months post-
transplant (unpublished observations).
Flow cytometric analyses of peripheral blood from BLT mice demonstrated the presence of
human CD4+ and CD8+ T cells, B cells, plasmacytoid and myeloid dendritic cells (DC) and
monocytes. In addition, small populations of NK, NKT and gamma-delta T cells have also
been reported (Melkus et al., 2006, Rajesh et al., 2010, Brainard et al., 2009, Lan et al.,
2006). Comparison of the relative levels of the different lymphoid subsets present in the
peripheral blood of humans and BLT mice demonstrates a striking similarity (Melkus et al.,
2006). Furthermore, like in humans, the T cells of BLT mice display a highly diverse Vβ-T
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cell receptor repertoire (Melkus et al., 2006). Thus, the peripheral blood of BLT mice
mimics that of human peripheral blood both in its cellular composition and in the relative
levels of human immune cell populations present.
2.3. Systemic human immune cell reconstitution of humanized BLT mice
The distribution of human cells in BLT mice is not limited to peripheral blood, rather it is
systemic (Fig. 1). Analysis of the tissue distribution of human immune cell populations
throughout BLT mice revealed an appropriate distribution of human lymphoid (B cells and
T cells) and myeloid (monocytes/macrophages and DCs) cells in all tissues analyzed
including the bone marrow, spleen, lymph nodes, liver, lung and the gastrointestinal (GI)
tract (Brainard et al., 2009,Sun et al., 2007,Rajesh et al., 2010,Melkus et al., 2006).
In humans, the GI tract is a major site of HIV-1 replication and CD4+ T cell depletion
regardless of the route of transmission (Brenchley et al., 2004, Mehandru et al., 2004). In
humanized BLT mice, human T, B and myeloid cells are found throughout the epithelium
and lamina propria of the small and large intestines (Sun et al., 2007, Denton et al., 2008).
Memory CD4+ and CD8+ T cells represent the majority of the T cells found in the intestines,
only a few naïve T cells are present. The fact that human lymphoid reconstitution extends to
the distal end of the lower GI tract renders BLT mice susceptible to rectal HIV-1
transmission that, like described above for humans, results in CD4+ T cell depletion
throughout the entire GI tract (Sun et al., 2007, Denton et al., 2008).
These analyses highlight the multi-lineage human immune cell reconstitution observed in
lymphoid, non-lymphoid and mucosal tissues of BLT mice including relevant sites of HIV-1
replication and pathogenesis, such as the GI tract (Denton et al., 2008, Sun et al., 2007,
Brenchley et al., 2004, Mehandru et al., 2004). Since the extensive and faithful human
lymphoid reconstitution observed in the GI tract of BLT mice renders them susceptible to
rectal HIV-1 transmission, a second mucosal site also important for HIV-1 transmission, the
FRT, was examined for the presence of human lymphoid cells in BLT mice (Denton et al.,
2008). These observations represent the focus of this review article.
3. Characterization of human immune cell reconstitution in the FRT of
humanized BLT mice
3.1. Comparison of the human and mouse FRT
Worldwide the majority of new HIV-1 infections occur in women (UNAIDS, 2009). Even
though rectal transmission does occur in women, vaginal exposure is the main route of
HIV-1 transmission to women (UNAIDS, 2006). In this particular context, either cell-free or
cell-associated virus present in the male ejaculate represents the infectious inoculum
(Mermin et al., 1991, Pudney and Anderson, 1991, Vernazza et al., 1994). After vaginal
exposure, the main possible portals of entry for HIV are the mucosal surfaces of the vagina,
ectocervix, endocervix and uterus (Miller et al., 1992, Kell et al., 1992, Li et al., 2009,
Howell et al., 1997). The gross anatomy of these key sites for HIV entry in the FRT is
similar in mice and humans (Fig. 2A). In the mouse FRT, separate uterine horns merge
caudally to form the corpus uteri which is internally divided by a midline septum (Leppi,
1964). The most caudal part of the uterus is the cervix consisting of a single endocervical
canal and the ectocervix which protrudes into the cranial portion of the vagina (Leppi,
1964), similar to the anatomy of the human cervix and vagina. Therefore, despite some
obvious anatomical differences (such as relative size and a duplex uterus), the mouse and
human FRT show similarities at postulated key sites of HIV entry making humanized BLT
mice a potentially relevant model for vaginal HIV transmission.
Olesen et al. Page 4













3.2. Identity and distribution of immune cells in the human FRT
The epithelial structure of the genital mucosa and the distribution of immune cells in the
mucosa differ throughout the vagina, ectocervix, endocervix and uterus of the human FRT.
The vagina and ectocervix are lined by stratified squamous epithelium, whereas the
endocervix and uterus are lined by simple columnar epithelium. It is proposed that the
stratified squamous epithelium of the ectocervix and vagina is a more resistant mechanical
barrier to HIV entry than the simple columnar epithelium of the endocervix and uterus
(Haase, 2010). Macrophages, plasma cells and B cells are dispersed throughout the lamina
propria of the vagina, ectocervix, endocervix and uterus (Kamat and Isaacson, 1987,
Hussain et al., 1992, Pudney et al., 2005, Yeaman et al., 1997). DCs are mainly present in
the epithelium but are also found scattered throughout the lamina propria (Pudney et al.,
2005).
T cells are the most abundant leukocytes in the vaginal, ectocervical, endocervical and
uterine mucosa (Kamat and Isaacson, 1987, Givan et al., 1997, Pudney et al., 2005). The
majority of T cells are concentrated in a band along the basement membrane just beneath the
epithelium (Johansson et al., 1999, Pudney et al., 2005). T cells are also found dispersed
throughout the epithelium and lamina propria (Johansson et al., 1999, Pudney et al., 2005).
The abrupt transition from squamous to columnar epithelium at the ecto-endocervical border
(the squamocolumnar junction) is termed the transformation zone. The density of T cells in
the transformation zone is higher than in the vagina, ectocervix and endocervix (Pudney et
al., 2005). The combination of abundant T cells, the appearance of columnar epithelium and
the high cell turnover rate in the transformation zone has led to the hypothesis that it might
be especially susceptible to HIV-1 infection as has been shown in the SIV/macaque models
(Li et al., 2009, Pudney et al., 2005, Haase, 2010).
3.3. Cellular targets for HIV-1 infection in the human FRT
The mucosal epithelium of the FRT by itself is an effective barrier against infection
(Bobardt et al., 2007) such that not all exposures to HIV-1 result in productive infection.
The overall transmission rate for HIV-1 is 0.1 – 10% per penile-vaginal contact (Powers et
al., 2008). There are three key scenarios that increase the likelihood of vaginal HIV-1
transmission: 1) when the index partner has early (primary infection) or late state disease
(AIDS), times when viral shedding in genital secretions is high, 2) when the index partner
has genital ulcers, which increases viral shedding in genital secretions and 3) when the
recipient partner has genital ulcers, which create breaches in the epithelial layer and have an
increased density of potential target cells due to local inflammation (Wawer et al., 2005,
Gray et al., 2001, Quinn et al., 2000, Powers et al., 2008). After vaginal exposure HIV-1
may gain access to target cells by penetrating breaches in the epithelium caused by micro-
trauma during sexual intercourse (Norvell et al., 1984). However, even in situations where
there is no trauma or ulcers, HIV-1 is occasionally capable of overcoming these natural
barriers and establishing a productive infection (Gupta et al., 2002, Maher et al., 2005, Nazli
et al., 2010).
The identity and the location of the initial cells involved in HIV-1 transmission are a subject
of great debate. Potential ways of establishing infection in the absence of mucosal disruption
include epithelial transcytosis and viral translocation across the epithelium (Bobardt et al.,
2007, Nazli et al., 2010). In addition, intra-epithelial Langerhans cells (LC) have long been
considered as potentially playing an important role in HIV-1 transmission (Arrighi et al.,
2004, McDonald et al., 2003, Geijtenbeek et al., 2000). More recent experiments have
demonstrated that LCs can internalize HIV-1 by endocytosis, after which HIV-1 can survive
in the cytoplasm and possibly trans-infect neighboring CD4+ T cells (Hladik et al., 2007).
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Similarly, DCs have also been postulated as playing an important role in vaginal HIV-1
transmission and virus spread (Miller and Hu, 1999, Geijtenbeek et al., 2000).
However, the mucosa of the human FRT contains a large number of CD4+ T cells (Hladik et
al., 2007, Saba et al., 2010, Pudney et al., 2005, Johansson et al., 1999) and experiments in
both non-human primates and human explant models suggest that the first productively
infected cells are CD4+ T cells (Gupta et al., 2002, Hladik et al., 2007, Zhang et al., 1999).
Additional experimental evidence suggests that only a single or a few viruses “seed” the
infection in one or a small founder population of regional CD4+ T cells (Keele et al., 2008,
Miller et al., 2005, Li et al., 2009, Maher et al., 2005) and that resting T cells account for
almost 90% of the productively infected cells shortly after vaginal exposure in macaques
(Zhang et al., 1999, Zhang et al., 2004).
3.4. Human immune cells in the FRT of BLT mice
In order for humanized BLT mice to serve as an adequate model to evaluate vaginal HIV-1
transmission, it is essential that the FRT of these mice are faithfully repopulated with the
appropriate human immune cells. Immunohistochemical analyses of the FRT from BLT
mice demonstrate an abundance of human hematopoietic cells located throughout the entire
vagina, ectocervix, endocervix and uterus (Fig. 2B) (Denton et al., 2008). Specifically,
analyses of the vagina, ectocervix, endocervix and uterus demonstrated the presence of
human T cells, macrophages and DCs (Denton et al., 2008).
A more detailed microscopic analysis of the human T cells present in the FRT of BLT mice
demonstrated that they are located within the epithelial layer, as a band at the epithelial-
lamina propria junction along the basement membrane and throughout the lamina propria
(Denton et al., 2008). This distribution of human T cells is very similar to the distribution of
the same cells in the human vagina, ectocervix and endocervix (Johansson et al., 1999,
Pudney et al., 2005). Furthermore, there are macrophages and DCs present in the lamina
propria throughout the FRT of BLT mice also like in humans (Denton et al., 2008). In
summary, the entire FRT of humanized BLT mice is well reconstituted with human
hematopoietic cells. All of the cells postulated as playing an important role in HIV-1
transmission are present in the FRT of BLT mice and their distribution resembles the
location of each specific cell type as normally found in humans.
Now that the human hematopoietic subsets considered to have an important role in HIV-1
transmission have been identified throughout the entire FRT of humanized BLT mice, the
utility of BLT mice as a model for HIV-1 vaginal transmission can be expanded by
performing a more detailed analysis of the human component of the FRT. Additional
information regarding the following aspects of the FRT of BLT mice will be essential for
future studies: 1) a comprehensive phenotypic characterization of the human immune cell
subsets present in the FRT, 2) an analysis of the human immune cell populations present in
vaginal fluids from BLT mice, 3) a detailed description of the cytokines present in the FRT
and vaginal fluids and 4) a study of the changes occurring in the human immune cell
populations and cytokine levels in the FRT during the different stages of the mouse estrus
cycle.
4. Mucosal HIV-1 transmission in humanized BLT mice
4.1. Vaginal exposure of humanized BLT mice to HIV-1 results in efficient virus
transmission
Based on the very encouraging results describing the substantial repopulation of the FRT of
BLT mice with human cells, vaginal HIV-1 transmission experiments were performed to
evaluate their susceptibility to infection via this highly relevant route of exposure in humans.
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Vaginal transmission of HIV-1 in BLT mice was tested by placing a single cell-free dose of
the CCR5-tropic primary isolate HIV-1JR-CSF directly into the vagina using an atraumatic
delivery technique (Denton et al., 2008). To ensure a highly reproducible exposure to the
inoculum and to facilitate its retention in the vagina, mice are maintained under anesthesia
during the inoculation procedure. Evidence of infection as determined by the presence of
plasma p24 and/or plasma HIV-RNA can be detected as early as two weeks after vaginal
exposure. Under these conditions, transmission has been documented in 88% of exposed
mice (Denton et al., 2008). Hence, humanized BLT mice are highly susceptible to vaginal
HIV-1 transmission, suggesting the potential utility of this system for a detailed in vivo
evaluation of the sequence of events involved in vaginal HIV-1 transmission and subsequent
dissemination.
4.2. Vaginal exposure to HIV-1 results in systemic infection and depletion of CD4+ cells
Once systemic infection is established following vaginal HIV-1 exposure (as early as 2
weeks post-exposure) of BLT mice, there is a progressive drop in the proportion of human
CD4+ T cells in peripheral blood. This loss of CD4+ T cells closely recapitulates the loss of
these same cells observed during acute HIV-1 infection of humans where the acute infection
phase is followed by a stabilization of CD4+ T cell levels in peripheral blood. Subsequent to
local transmission occurring at the FRT, HIV-1 is rapidly disseminated throughout all
tissues in BLT mice. Evidence of productively infected cells as determined by in situ
hybridization is clearly seen at primary/secondary and immunoregulatory sites (Fig. 3A). In
addition, productively infected cells are clearly present in virtually all other mouse tissues
like the heart and pancreas (unpublished data). All the tissues evaluated reflect the reduced
levels of CD4+ T cells observed in peripheral blood demonstrating the systemic depletion of
these cells throughout the animal (Denton et al., 2008).
4.3. Vaginal HIV-1 infection results in human CD4+ T cell depletion in the GI Tract
In humans, HIV-1 infection of the GI tract results in depletion of CD4+ T cells (Brenchley et
al., 2004, Mehandru et al., 2004). Therefore, the dissemination of HIV-1 to the GI tract of
BLT mice after vaginal exposure is of particular importance and high relevance. As
indicated above, the GI tract of humanized BLT mice is faithfully reconstituted with human
lymphoid cells permitting the analysis of the sequela of vaginal HIV-1 transmission in both
the small and large intestine. Vaginal HIV-1 transmission in BLT mice leads to
disseminated infection of the entire GI tract. Infected cells can be clearly identified in the
lamina propria and epithelium of the small intestine (Denton et al., 2008). Infection of the
GI tract results in a dramatic loss of human CD4+ T cells in this tissue (Fig. 3B).
Furthermore, there is a specific and substantial loss of CD45RAnegCD27negCD4+effector
memory cells in these tissues (Denton et al., 2008). This is a well-described characteristic of
human HIV-1 infection and of macaque SIV/SHIV infection that is faithfully recapitulated
in humanized BLT mice (Veazey et al., 2000, Mehandru et al., 2004).
5. Evaluation of approaches to prevent vaginal HIV-1 transmission in
humanized BLT mice
As indicated above, in the absence of an effective vaccine or other successful preventive
strategies, the AIDS epidemic continues to spread at an alarming rate. Vaginal transmission
is responsible for the majority of new infections worldwide (UNAIDS, 2006). Therefore,
there is a critical need for the development and implementation of strategies to prevent
vaginal HIV-1 transmission. Beyond vaccines, there are two different preventative strategies
currently being considered: topically applied microbicides and systemically administered
antiretrovirals to individuals at high risk (targeted systemic PrEP) (Padian et al., 2010,
Garcia-Lerma et al., 2010). The development and preclinical efficacy testing of topical
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microbicides and other preventive strategies, such as targeted systemic antiretroviral PrEP,
is dependent on the availability of adequate animal models. Until the development of
humanized mice the most used surrogate animal model used to study vaginal HIV-1
transmission and prevention were non-human primates infected with SIV or SHIVs (Van
Rompay, 2010, Uberla, 2005, Denton and Garcia, 2009, Garcia-Lerma et al., 2010). Using
humanized mice to evaluate HIV-1 prevention approaches is of high significance because it
allows the study of HIV-1 infection of human cells in the highly relevant context of the
entire FRT in vivo.
5.1. Important considerations regarding the evaluation of PrEP approaches for the
prevention of vaginal HIV-1 transmission in humanized BLT mice
The concept of targeted systemic PrEP involves the continuous treatment of HIV-1-negative
individuals at high risk for acquiring HIV-1 with antiretroviral drugs in an effort to prevent
HIV-1 transmission (Garcia-Lerma et al., 2010). However, there are major concerns
regarding the potential side effects of the drugs used because systemic PrEP entails the
administration of antiretroviral drugs to large numbers of otherwise healthy individuals
(Derdelinckx et al., 2006). In addition, there is also the potential danger that drug resistant
viruses may develop in individuals who unknowingly become infected with HIV-1 and
continue to receive systemic PrEP, ultimately resulting in the spread of drug resistant viruses
(Supervie et al., 2010). Therefore, there is significant interest in the development and
implementation of animal models in which these concerns can be addressed experimentally.
For its clinical implementation, it is essential that any candidate drug be safe, highly
efficacious and easy to use in order to maximize patient compliance (Derdelinckx et al.,
2006). Experiments in BLT mice have successfully demonstrated the efficacy of systemic
PrEP against vaginal HIV-1 infection using emtricitabine and tenofovir disoproxil fumarate
(FTC/TDF, the combination of drugs present in Truvada®) (Denton et al., 2008). The
combination of FTC/TDF was chosen because it meets important criteria for drugs included
as potential candidates for clinical trials of systemic PrEP; high potency, favorable toxicity
profiles, relatively high threshold for the development of viral resistance and its once daily
administration without food restrictions (De Clercq, 2007, Derdelinckx et al., 2006).
5.2. Systemic administration of FTC/TDF efficiently prevents vaginal HIV-1 transmission in
humanized BLT mice
The evaluation of PrEP in humanized mice was designed to reflect as closely as possible its
implementation in humans. Specifically, humanized BLT mice were generated and carefully
validated for their reconstitution with human cells prior to treatment. Treatment consisted of
FTC/TDF administered systemically once per day for seven days. On the third day of
treatment, mice were challenged intravaginally with a high dose of HIV-1. Mice were then
monitored over time for the presence of any evidence of infection. Control (untreated) BLT
mice were readily infected under these experimental conditions (Denton et al., 2008) as
determined by the presence of readily detectable HIV in plasma. In contrast, daily treatment
with FTC/TDF resulted in complete absence of any evidence of HIV infection in the
peripheral blood of the treated mice (Denton et al., 2008). Complete protection from HIV
infection was confirmed by systemic molecular and cellular analyses for the presence of any
signs of infection. Specifically, in protected animals there was no evidence of viral
antigenemia, viral RNA, viral DNA or productively infected cells in any tissue at any time
point analyzed (Denton et al., 2008). These results demonstrate the strong protective effect
of FTC/TDF against vaginal HIV-1 infection in BLT mice and also emphasize the
applicability of BLT mice for preclinical evaluation of PrEP approaches to prevent vaginal
HIV-1 transmission.
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Vaginal infection is the predominant mode of HIV-1 transmission globally. The FRT is
therefore one of the major locations for natural HIV-1 infection and any efforts aimed at
preventing HIV-1 transmission to women (including vaccines) must successfully establish
protection at this specific portal of virus entry. Despite advances obtained through studies
using ex vivo tissue explants of the human FRT and non-human primates, vaginal HIV-1
transmission in humans is still not fully understood (Haase, 2010).
The availability of robust animal models such as BLT mice that recapitulate key aspects of
HIV-1 transmission as they might occur in humans provides opportunities to further study
details of vaginal transmission as well as the effects of acute and chronic HIV-1 infection. In
addition, BLT mice allow for HIV-1 infection studies of human cell targets in vivo at the
most relevant mucosal sites. The usefulness of BLT mice in testing HIV-1 prevention
strategies has already been demonstrated by the efficient protection against vaginal HIV-1
transmission afforded by PrEP as described in this review. The susceptibility of BLT mice to
mucosal HIV-1 transmission also allows the testing of different microbicide candidates.
Importantly, the fact that thymocytes in BLT mice are educated in the context of HLA (in
the developed human thymic organoid) makes this model highly relevant for evaluating
human-specific immune responses to potential HIV-1 vaccines.
In conclusion, the recent development of humanized BLT mice and their validation as a
highly relevant small animal model for the study of HIV-1 provides the field of HIV
research with a powerful new tool. This model permits study of the earliest events of HIV-1
transmission and the pathogenic mechanisms of the virus during infection. Finally, BLT
mice can be used to systematically analyze the efficacy of HIV-1 prevention, therapeutic
and eradication interventions; key experiments aimed at stopping the spread of HIV-1.
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Fig. 1. Human immune cell reconstitution of BLT mice
(A) The primary and secondary lymphoid organs of BLT mice are reconstituted with human
hematopoietic (CD45+) cells. The percentage of human CD45+ cells in the bone marrow
(BM; n=26), thymic organoid (TO; n=26), spleen (n=26) and lymph nodes (LN; n=16) of
BLT mice was determined with flow cytometric analyses. (B) Human hematopoietic cells
were also found in peripheral blood (PB; n=22), the lung (n=9) and liver (n=7). In addition
small intestine lamina propria lymphocytes (SI LPL; n=23) and small intestine intra-
epithelial lymphocytes (SI IEL; n=23) have been described.
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Fig. 2. Reconstitution of the FRT of BLT mice with human hematopoietic cells
(A) Diagram depicting the mouse uterus, cervix and vagina (separated by dashed lines in the
figure). (B) Immunohistochemical analysis of the vagina, ectocervix, endocervix and uterus
of female BLT mice demonstrating the presence of human hematopoietic cells (stained
brown). Robust reconstitution with cells relevant to HIV infection, including human T cells
(CD3+), monocyte/macrophages (CD68+) and dendritic cells (CD11c+) is observed in each
compartment of the FRT, demonstrating its efficient repopulation (bars indicate 25 µm)
(Denton et al., 2008).
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Fig. 3. Transmission after vaginal HIV-1 exposure results in disseminated HIV-1 infection and
depletion of CD4+ T cells in the GI tract
(A) In situ hybridization analysis for the presence of productively infected cells in multiple
tissues from BLT mice vaginally exposed to HIV-1 (bars indicate 50µm). (B) Comparison of
the CD4+ and CD8+ human T cells levels in the small intestine intra-epithelial lymphocytes
(SI IEL) and lamina propria lymphocytes (SI LPL) and the large intestine intra-epithelial
lymphocytes (LI IEL) and lamina propria lymphocytes (LI LPL) of naive and HIV-1
infected mice (Denton et al., 2008).
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